Bristol Myers Squibb Company (BMY) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bristol myers Squibb Company  (NYSE: BMY)


Bristol Myers Squibb's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Bristol Myers Squibb's ROI in the second quarter of 2026?
Bristol myers Squibb Company achieved a return on average invested assets (ROI) of 13.58 % in its second quarter of 2026, this is above BMY's average return on investment of 11.17%.
Bristol Myers Squibb Companys investments during the 12 months ending in the second quarter of 2026 are valued at $68 billion

ROI has improved compared to 10.72% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 78 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 744 to 768.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -0.87 % -3 % -4.28 % 6.51 % 8.77 %
Y / Y Net Income Change TTM 83.06 % 33.73 % 137.14 % 108.55 % 200.83 %
Investment (TTM) in Millions 68,975 67,352 68,062 68,801 67,202
Return On Investment (TTM) 13.58 % 10.72 % 10.36 % 8.85 % 7.35 %
BMY's Overall Ranking # 768 # 744 # 671 # 861 # 912
Seq. Investment Change TTM 0.65 % -0.39 % -0.3 % -0.83 % -1.51 %
Seq. Net Income Change TTM 27.55 % 3.06 % 16.69 % 19.34 % -6.82 %
Net Income (TTM) in Millions 9,274 7,271 7,055 6,046 5,066

BMY Company Profile >> Back to BMY Roi Comparisons >> See Annual BMY Return On Investment



Return On Investment BMY's Ranking
Within: No.
Industry # 34
Sector # 79
Overall # 768

Return On Investment Statistics
High Average Low
44.98 %
11.17 %
-12.55 %
(Dec. 31, 2009)   (Dec 31 2024)







Financial Statements
Bristol Myers Squibb's II. Quarter Investments $ 68,975 Millions BMY's Balance sheet
Bristol Myers Squibb's II. Quarter Income $ 3,316 Millions Quarterly BMY's Income Statement
BMY's Income by Division See BMY's Income by Division


BMY Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 66,655 68,882 72,952 74,987 87,506
Y / Y Investment Growth -3.23 % -5.58 % -2.71 % -14.31 % -12.02 %
Net Income in Millions 7,055 -8,933 8,040 6,345 7,014
Y / Y Net Income Growth - - 26.71 % -9.54 % -
Annual Return On Investment 10.58 % -12.97 % 11.02 % 8.46 % 8.02 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 10.58 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BMY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BMY's Competitors
Subscribers only: Roi for Bristol Myers Squibb's Suppliers
Subscribers only: Return On Investment for BMY's Customers

Other Ratios
BMY's Roa BMY's Inventory Turnover Ratio BMY's Growth Rates BMY's Dividend Statistics
BMY's Profitability Ratios BMY's Asset Turnover Ratio BMY's Dividend Growth
BMY's Roe BMY's Valuation Ratios BMY's Financial Strength Ratios BMY's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %

Date modified: 2026-09-14T03:49:14+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.